Entero Therapeutics receives noncompliance notification from Nasdaq

Entero Therapeutics announced that it received a letter from Nasdaq advising that, because the company failed to timely file its quarterly report on Form 10-Q for the fiscal quarter ended June 30, the company was not in compliance with Nasdaq Listing Rule 5250. Nasdaq has informed the company that it has until October 21 to submit a plan to regain compliance with the rule. If Nasdaq approves the company’s plan, it has the discretion to grant the company an extension of up to 180 calendar days from the due date of the Form 10-Q to regain compliance.